Background
==========

AntiRo are found in 5--15% of RA. Significant associations were reported with sicca, vasculitis, hypergammaglobulins, ANA, high-titer RF, toxicity to D-penicillamine and gold salts treatment. Aim of the study: to evaluate clinical features, radiologic progression and response to disease-modifying antirheumatic drugs (DMARDs) in antiRo-RA patients.

Patients and methods
====================

We studied 210 patients with RA: antiRo were determined by CIE, with human spleen extract, and by ELISA with recombinant Ro proteins (Pharmacia). Cutoff values for ELISA were determined testing 177 sera from routine.

Results
=======

AntiRo were detected in 27 patients (F:M 12.5:1). Two groups (antiRo^+^ and antiRo^-^) did not show any difference with regard to disease duration, arthritis onset and articular erosions. AntiRo were associated with xerophthalmia (*P* \< 0.0000001), xerostomia (*P* = 0.0012), oral ulcers (*P* = 0.0067), scleritis (*P* = 0.0067) and amyloidosis (*P* = 0.042). Rheumatoid factor, antiperinuclear factor and anticitrulline were recorded in 70% in both groups; hypergammaglobulinemia, ANA, anti-dsDNA and AMA were frequently detected in antiRo^+^ patients. Patients were given a mean of 3.93 DMARDs, with no statistical difference between antiRo^+^ and antiRo^-^: hydroxychloroquine, methotrexate and gold salts are the most frequently used. Patients who were antiRo^-^ were more frequently treated with hydroxychloroquine and infliximab, while D-penicillamine was used more frequently in those who were antiRo^+^. DMARD toxicity was detected in 9.3% of antiRo^+^, with no statistically significant difference between the two groups.

Conclusion
==========

AntiRo, found in 12.8% of patients with RA, is associated with extra-articular features and with an autoantibody profile unusual for RA. No difference with respect to DMARD toxicity was found in anti-Ro^+^ patients.
